(P313) Identifying Risk Factors for Immune Checkpoint Inhibitor-Induced Diabetes: An Integrative Review

With the emergence of immunotherapy, survival outcomes have improved up to 6.5 years, changing the outlook for those with terminal malignancy. However, immunotherapy does not come without risk. It can cause the body to attack normal healthy cells, such as the beta cells of the pancreas. The primary purpose of the pancreas's beta cells is to produce insulin. The destruction of insulin production leads to the development of a condition called immune checkpoint inhibitor diabetes (ICI-DM). This poster outlines how the incidence of this condition is slowly rising with increased use of immunotherapy, now reported to occur in 3% of individuals exposed to this treatment. There is a gap in evidence identifying what places some individuals at increased risk for this condition. Authors: Vivian Crowder MSN, APRN, FNP-C, AOCNP, BC-ADM, University of Texas Cizik School of Nursing; Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDCES, University of Texas Cizik School of Nursing, Assistant Professor. Funding Source: None.